Skip to main content

Table 3 Summary of the most frequent adverse events that occurred during the study (frequency ≥ 10% of patients)

From: Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study

  Number of patients (%)
Adverse event (preferred term) Placebo (n = 16) IFN beta-1a 44 mcg biw (n = 17) IFN beta-1a 44 mcg tiw (n = 16) IFN beta-1a 66 mcg tiw (n = 18) Total (n = 67)
Influenza-like symptoms 3 (18.8) 8 (47.1) 6 (37.5) 7 (38.9) 24 (35.8)
Headache 3 (18.8) 8 (47.1) 7 (43.8) 4 (22.2) 22 (32.8)
Injection-site reaction 2 (12.5) 5 (29.4) 6 (37.5) 5 (27.8) 18 (26.9)
Fever 2 (12.5) 3 (17.6) 5 (31.3) 6 (33.3) 16 (23.9)
Abdominal pain 4 (25.0) 2 (11.8) 5 (31.3) 5 (27.8) 16 (23.9)
Injection-site inflammation 2 (12.5) 3 (17.6) 5 (31.3) 5 (27.8) 15 (22.4)
Fatigue 3 (18.8) 3 (17.6) 4 (25.0) 2 (11.1) 12 (17.9)
Nausea 3 (18.8) 3 (17.6) 2 (12.5) 3 (16.7) 11 (16.4)
ESR increased 0 2 (11.8) 5 (31.3) 3 (16.7) 10 (14.9)
Arthralgia 2 (12.5) 4 (23.5) 3 (18.8) 1 (5.6) 10 (14.9)
Injection-site rash 0 3 (17.6) 3 (18.8) 2 (11.1) 8 (11.9)
Rhinitis 2 (12.5) 2 (11.8) 3 (18.8) 1 (5.6)_ 8 (11.9)
Myalgia 1 (6.3) 4 (23.5) 2 (12.5) 1 (5.6) 8 (11.9)
Injection-site pain 0 2 (11.8) 1 (6.3) 4 (22.2) 7 (10.4)
Anaemia 0 4 (23.5) 2 (12.5) 1 (5.6) 7 (10.4)
  1. biw: twice weekly; ESR: erythrocyte sedimentation rate; IFN: interferon; tiw: three times weekly